Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1979 Mar 1;149(3):745–757. doi: 10.1084/jem.149.3.745

The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination

PMCID: PMC2184829  PMID: 429962

Abstract

The tumor dormant state established in L5178Y immunized and challenged mice is characterized by a prolonged period of clinical normalcy followed by rapid tumor outgrowth. The tumor cells which emerged after termination of the tumor dormant state had abnormal marker chromosomes identical to those in the L5178Y cells used in the original challenge inoculum, indicating that the emergent tumor cells were progeny of the challenge inoculum. Original and emergent L5178Y cells had equivalent in vivo growth rates, when inoculated into normal DBA/2 mice. The emergent L5178Y cells were less susceptible than original cells to in vitro lysis by tumor dormant PC. Original and emergent L5178Y cells expressed common tumor-associated target antigens for cytolytic effector cells. Both modulation and masking of these target antigens were ruled out as mechanisms for decreased susceptibility to cell- mediated cytolysis. Immunofluorescence revealed heterogeneity in tumor- associated antigen expression within both original and emergent cell populations, with a decreased intensity of staining in the emergent population. Both populations were equally susceptible to lysis by alloimmune cells, alloantiserum, and anti-Thy 1.2 serum, but emergent cells were less susceptible to lysis by serum directed against L5178Y TAA. Quantitative absorption revealed that the emergent L5178Y cells expressed eightfold less serologically detectable TAA than the original cells. These findings indicate that the host immune response developing during establishment of the tumor dormant state selects a stable tumor cell subpopulation which expresses decreased amounts of surface tumor- associated target antigens.

Full Text

The Full Text of this article is available as a PDF (985.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Ghazzouli I. K., Donahoe R. M., Huang K. Y., Sass B., Peters R. L., Kelloff G. J. Immunity to virus-free syngeneic tumor cell transplantation in the BALB/c mouse after immunization with homologous tumor cells infected with type C virus. J Immunol. 1976 Dec;117(6):2239–2248. [PubMed] [Google Scholar]
  2. Allan E. Breast cancer: the long latent interval. Eur J Cancer. 1977 Aug;13(8):839–845. doi: 10.1016/0014-2964(77)90139-6. [DOI] [PubMed] [Google Scholar]
  3. BASERGA R., KISIELESKI W. E., HALVORSEN K. A study on the establishment and growth of tumor metastases with tritiated thymidine. Cancer Res. 1960 Jul;20:910–917. [PubMed] [Google Scholar]
  4. Bagshawe K. D., Currie G. A. Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase. Nature. 1968 Jun 29;218(5148):1254–1255. doi: 10.1038/2181254a0. [DOI] [PubMed] [Google Scholar]
  5. Biddison W. E., Palmer J. C. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci U S A. 1977 Jan;74(1):329–333. doi: 10.1073/pnas.74.1.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Currie G. A., Bagshawe K. D. Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer. 1969 Mar;23(1):141–149. doi: 10.1038/bjc.1969.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Doherty P. C., Blanden R. V., Zinkernagel R. M. Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity. Transplant Rev. 1976;29:89–124. doi: 10.1111/j.1600-065x.1976.tb00198.x. [DOI] [PubMed] [Google Scholar]
  8. Fenyö E. M., Klein E., Klein G., Swiech K. Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. J Natl Cancer Inst. 1968 Jan;40(1):69–89. [PubMed] [Google Scholar]
  9. Fialkow P. J., Klein E., Klein G., Clifford P., Singh S. Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med. 1973 Jul 1;138(1):89–102. doi: 10.1084/jem.138.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fidler I. J., Gersten D. M., Budmen M. B. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res. 1976 Sep;36(9 PT1):3160–3165. [PubMed] [Google Scholar]
  11. Klein G., Klein E., Haughton G. Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst. 1966 Apr;36(4):607–621. doi: 10.1093/jnci/36.4.607. [DOI] [PubMed] [Google Scholar]
  12. Mark J. Chromosomal abnormalities and their specificity in human neoplasms: an assessment of recent observations by banding techniques. Adv Cancer Res. 1977;24:165–222. doi: 10.1016/s0065-230x(08)61015-5. [DOI] [PubMed] [Google Scholar]
  13. Miller D. A., Firschein I. L., Dev V. G., Tantravahi R., Miller O. J. The gorilla karyotype: chromosome lengths and polymorphisms. Cytogenet Cell Genet. 1974;13(6):536–550. doi: 10.1159/000130305. [DOI] [PubMed] [Google Scholar]
  14. Parker G. A., Rosenberg S. A. Cross-reacting antigens in chemically induced sarcomas are fetal determinants. J Immunol. 1977 May;118(5):1590–1594. [PubMed] [Google Scholar]
  15. Pimm M. V., Baldwin R. W. Antigenic differences between primary methylcholanthrene-induced rat sarcomas and post-surgical recurrences. Int J Cancer. 1977 Jul 15;20(1):37–43. doi: 10.1002/ijc.2910200108. [DOI] [PubMed] [Google Scholar]
  16. Sanford B. H., Codington J. F. Further studies on the effect of neuraminidase on tumor cell transplantability. Tissue Antigens. 1971;1(4):153–161. doi: 10.1111/j.1399-0039.1971.tb00092.x. [DOI] [PubMed] [Google Scholar]
  17. Thomas E., Storb R., Clift R. A., Fefer A., Johnson F. L., Neiman P. E., Lerner K. G., Glucksberg H., Buckner C. D. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975 Apr 17;292(16):832–843. doi: 10.1056/NEJM197504172921605. [DOI] [PubMed] [Google Scholar]
  18. Trentin J. J. Tumor immunotherapy in experimental animals: current status and prospectus. Ann N Y Acad Sci. 1976;277(00):716–721. doi: 10.1111/j.1749-6632.1976.tb41744.x. [DOI] [PubMed] [Google Scholar]
  19. Weinhold K. J., Goldstein L. T., Wheelock E. F. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J Exp Med. 1979 Mar 1;149(3):732–744. doi: 10.1084/jem.149.3.732. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES